Treatment of relapsing acute promyelocytic leukemia by all-trans retinoic acid therapy followed by timed sequential chemotherapy and stem cell transplantation
Xavier Thomas(Hôpital Lyon Sud), Hervé Dombret(University of London Institute in Paris), Arnaud Pigneux(Centre Hospitalier Universitaire de Bordeaux), Françoise Huguet(Centre Hospitalier Universitaire de Toulouse), Agnès Buzyn(Hôpital Saint-Jacques), Pierre Fenaux(Saint Louis University Hospital), Christine Chomienne(Inserm), N Gratecos(Hôpital Purpan), JP Vilque(Hôpital Robert-Debré), Catherine Cordonnier(Université Paris-Est Créteil), Anne Vekhoff(Hôtel-Dieu de Paris), Thierry de Revel(Hôpital d'instruction des Armées Percy), Philippe Travade(European Union), Philippe Naccache(Institut Gustave Roussy), Alain Sadoun(Centre Hospitalier Universitaire de Lille), Claude Gardin(Sorbonne Université), Oumédaly Reman(University of Bern), Aspasia Stamatoullas(European Union), Nathalie Fegueux(European Union), F. Maloisel(Centre Hospitalier Universitaire de Lille), Christian Berthou(Centre Hospitalier Régional Universitaire de Brest), L Degos(Centre Hospitalier Universitaire de Lille), J Cahn(Leukemia Research Foundation), Pavel Kotouček, A. Guerci(University of Bern)
Cited by 99
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3.1k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k